Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPZM NASDAQ:KRTX NYSE:PBH NASDAQ:PRNB NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsPBHPrestige Consumer Healthcare$61.93+0.1%$64.78$60.15▼$90.04$3.04B0.44472,509 shs333,746 shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/AXNCRXencor$12.43-11.0%$9.40$6.92▼$27.24$995.67M0.961.27 million shs2.90 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPZMEpizyme0.00%0.00%0.00%0.00%0.00%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%PBHPrestige Consumer Healthcare+0.16%-1.47%-2.18%-17.52%-11.63%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%XNCRXencor-10.96%+3.33%+44.53%+40.77%-40.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsPBHPrestige Consumer Healthcare$61.93+0.1%$64.78$60.15▼$90.04$3.04B0.44472,509 shs333,746 shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/AXNCRXencor$12.43-11.0%$9.40$6.92▼$27.24$995.67M0.961.27 million shs2.90 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPZMEpizyme0.00%0.00%0.00%0.00%0.00%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%PBHPrestige Consumer Healthcare+0.16%-1.47%-2.18%-17.52%-11.63%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%XNCRXencor-10.96%+3.33%+44.53%+40.77%-40.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPZMEpizyme 0.00N/AN/AN/AKRTXKaruna Therapeutics 0.00N/AN/AN/APBHPrestige Consumer Healthcare 2.43Hold$94.8053.08% UpsidePRNBPrincipia Biopharma 0.00N/AN/AN/AXNCRXencor 2.64Moderate Buy$24.2294.87% UpsideCurrent Analyst Ratings BreakdownLatest PBH, EPZM, XNCR, PRNB, and KRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025XNCRXencorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PBHPrestige Consumer HealthcareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025XNCRXencorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/6/2025XNCRXencorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.009/27/2025PBHPrestige Consumer HealthcareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025XNCRXencorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/24/2025PBHPrestige Consumer HealthcareSidotiSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$80.009/17/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$6.009/16/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell9/4/2025PBHPrestige Consumer HealthcareZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell9/3/2025XNCRXencorBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$23.00 ➝ $12.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72KRTXKaruna Therapeutics$654K19,239.07N/AN/A$33.24 per share9.92PBHPrestige Consumer Healthcare$1.14B2.68$5.22 per share11.86$37.04 per share1.67PRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14XNCRXencor$110.49M8.02N/AN/A$9.63 per share1.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AKRTXKaruna Therapeutics-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/APBHPrestige Consumer Healthcare$214.60M$4.2614.5413.011.9519.02%12.69%6.79%11/6/2025 (Estimated)PRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/AXNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest PBH, EPZM, XNCR, PRNB, and KRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q2 2026PBHPrestige Consumer Healthcare$1.01N/AN/AN/A$257.14 millionN/A11/5/2025Q3 2025XNCRXencor-$0.72N/AN/AN/A$29.73 millionN/A8/7/2025Q1 2026PBHPrestige Consumer Healthcare$1.01$0.95-$0.06$0.95$260.71 million$249.53 million8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPZMEpizymeN/AN/AN/AN/AN/AKRTXKaruna TherapeuticsN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPZMEpizymeN/A5.355.19KRTXKaruna TherapeuticsN/A19.3119.31PBHPrestige Consumer Healthcare0.554.382.99PRNBPrincipia BiopharmaN/A17.0117.01XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPZMEpizyme76.45%KRTXKaruna TherapeuticsN/APBHPrestige Consumer Healthcare99.95%PRNBPrincipia Biopharma95.54%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipEPZMEpizyme23.40%KRTXKaruna Therapeutics13.20%PBHPrestige Consumer Healthcare1.40%PRNBPrincipia Biopharma16.01%XNCRXencor5.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPZMEpizyme250168.33 million128.97 millionOptionableKRTXKaruna Therapeutics33938.15 million33.16 millionOptionablePBHPrestige Consumer Healthcare54049.21 million48.53 millionOptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableXNCRXencor28071.32 million67.59 millionOptionablePBH, EPZM, XNCR, PRNB, and KRTX HeadlinesRecent News About These CompaniesXencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on ...October 14 at 11:02 PM | finance.yahoo.comXencor price target raised to $14 from $12 at BofAOctober 14 at 6:00 PM | msn.comXencor slides amid plans for early-stage trial data for kidney cancer drugOctober 14 at 6:00 PM | msn.comXencor (NASDAQ:XNCR) Trading Down 13.3% - Should You Sell?October 14 at 2:06 PM | marketbeat.comXencor (NASDAQ:XNCR) Receives "Sell (D-)" Rating from Weiss RatingsOctober 14 at 12:48 PM | marketbeat.comXencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 14 at 12:45 PM | businesswire.comXencor Sees RS Rating Rise To 73October 13 at 12:37 AM | msn.comAnalysts Offer Predictions for Xencor FY2025 EarningsOctober 12 at 2:11 AM | americanbankingnews.comEquities Analysts Issue Forecasts for Xencor FY2025 EarningsOctober 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Upgraded at Cantor FitzgeraldOctober 11, 2025 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 11, 2025 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by AnalystsOctober 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Raised to Strong-Buy at Cantor FitzgeraldOctober 10, 2025 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Xencor (NASDAQ:XNCR)October 8, 2025 | americanbankingnews.comCantor Fitzgerald Forecasts Xencor FY2025 EarningsOctober 7, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Given "Overweight" Rating at Cantor FitzgeraldOctober 6, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading 6.2% Higher - Should You Buy?September 26, 2025 | marketbeat.comXencor: Bispecific Antibody Program Takes Shape With Q4 Data ReleaseSeptember 19, 2025 | seekingalpha.comXencor (XNCR) Receives a Sell from Roth MKMSeptember 19, 2025 | theglobeandmail.comXencor (NASDAQ:XNCR) Upgraded to "Strong Sell" at BarclaysSeptember 19, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading Up 5.4% - Time to Buy?September 18, 2025 | marketbeat.comMedia Sentiment Over TimePBH, EPZM, XNCR, PRNB, and KRTX Company DescriptionsEpizyme NASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Karuna Therapeutics NASDAQ:KRTXKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Prestige Consumer Healthcare NYSE:PBH$61.93 +0.09 (+0.14%) Closing price 10/14/2025 03:58 PM EasternExtended Trading$61.86 -0.07 (-0.11%) As of 10/14/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Principia Biopharma NASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Xencor NASDAQ:XNCR$12.43 -1.53 (-10.96%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$12.49 +0.06 (+0.48%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
